证券代码：300942 证券简称：易瑞生物 公告编号：2023-065 深圳市易瑞生物技术股份有限公司 关于投资者热线的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 深圳市易瑞生物技术股份有限公司（以下简称"公司"）为了进一步加强与 投资者之间的沟通和交流，方便投资者及时了解公司情况，现设置投资者热线直 线电话，直线号码为：0755-23095742。 上述投资者热线自本公告发布之日起正式启用，原投资者热线号码0755- 27948546转889继续有效。公司联系地址、传真、投资者电子邮箱等其他联系方 式均保持不变。敬请广大投资者注意。 特此公告。 深圳市易瑞生物技术股份有限公司 董事会 2023年8月9日 1 ...

证券代码：300942 证券简称：易瑞生物 编号：2023-002 投资者关系活动记录表 特定对象调研（线下） 分析师会议 投资者关系活 媒体采访 业绩说明会 动类别 新闻发布会 路演活动 现场参观 其他 参与单位名称 及人员姓名 线上参与公司 2022 年度网上业绩说明会的投资者 时间 2023 年 5 月 17 日 15:00-17:00 地点 全景网"投资者关系互动平台"（http://ir.p5w.net） 董事兼总经理肖昭理先生 上市公司接待 独立董事何祚文先生 人员姓名 财务总监兼董事会秘书万凯先生 东兴证券保荐代表人刘鸿斌先生 公司定于 2023 年 5 月 17 日（星期三）下午 15:00-17:00 在深圳 投资者关系活 证券信息有限公司提供的网上平台（全景网）举行 2022 年度网 动主要内容介 上业绩说明会，本次年度业绩说明会将采用网络远程的方式举 绍 行 ， 投 资 者 可 登 陆 全 景 网 " 投 资 者 关 系 互 动 平 台 " （http://ir.p5w.net）参与本次年度业绩说明会。 附件清单 《2022 年度网上业绩说明会互动问答主要内容记录表》 日期 2023 年 ...

为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2023年5月 16日（星期二）17:00前访问http://ir.p5w.net/zj/，或扫描下方二维码，进入问题征 集专题页面。公司将在2022年度业绩说明会上，对投资者普遍关注的问题进行回 答。欢迎广大投资者积极参与。 （问题征集专题页面二维码） 证券代码：300942 证券简称：易瑞生物 公告编号：2023-045 深圳市易瑞生物技术股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市易瑞生物技术股份有限公司（以下简称"公司"）已于2023年4月26日 在巨潮资讯网（www.cninfo.com.cn）披露了《2022年年度报告》及其摘要。 为使投资者进一步了解公司2022年度经营情况，公司将于2023年5月17日（星 期三）下午15:00-17:00在全景网举行2022年度网上业绩说明会，本次年度业绩说 明会将采用网络远程的方式举行，投资者可登陆全景网"投资 ...

Financial Performance - The company's revenue for Q1 2023 was ¥60,707,585.25, a decrease of 79.35% compared to ¥294,001,215.63 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥28,061,115.03, representing a decline of 124.59% from a profit of ¥114,128,972.49 in the previous year[4] - The basic earnings per share decreased to -¥0.07, down 125.00% from ¥0.28 in the same period last year[4] - The company reported a revenue of RMB 60.7076 million for Q1 2023, a decrease of 79.35% year-on-year[15] - The net profit attributable to shareholders was a loss of RMB 28.0611 million, representing a decline of 124.59% year-on-year[15] - The net profit for Q1 2023 was -28,085,394.84 CNY, compared to a net profit of 114,098,297.86 CNY in the same period last year, representing a significant decline[27] - Operating profit for Q1 2023 was -33,534,213.82 CNY, down from 139,280,317.86 CNY in Q1 2022[27] - The company reported a total comprehensive income of -28,042,280.58 CNY for Q1 2023, compared to 114,017,886.19 CNY in the same period last year[28] - Basic and diluted earnings per share for Q1 2023 were both -0.07 CNY, compared to 0.28 CNY in Q1 2022[28] Cash Flow and Assets - The company reported a net cash flow from operating activities of -¥53,990,719.10, which is a 5.50% increase in cash outflow compared to -¥51,177,229.38 in the previous year[4] - Cash and cash equivalents at the end of the first quarter were CNY 212,068,033.13, down from CNY 247,451,094.68 at the beginning of the year[21] - The total cash flow from operating activities was -53,990,719.10 CNY, compared to -51,177,229.38 CNY in the previous year, showing a slight worsening in cash flow[31] - Cash and cash equivalents at the end of Q1 2023 were 211,797,625.08 CNY, down from 303,982,289.69 CNY at the end of Q1 2022[32] - The company received 64,945,294.39 CNY in cash inflows from operating activities, a decrease from 202,641,561.46 CNY in the previous year[31] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,202,907,829.48, a decrease of 6.20% from ¥1,282,455,601.74 at the end of the previous year[4] - As of March 31, 2023, total assets amounted to CNY 1,202,907,829.48, a decrease from CNY 1,282,455,601.74 at the beginning of the year[23] - The total liabilities decreased to CNY 262,160,828.45 from CNY 317,754,458.88[24] - Inventory decreased to CNY 83,337,947.31 from CNY 100,608,210.17, indicating a reduction in stock levels[22] - Non-current assets increased to CNY 631,158,729.22 from CNY 608,036,291.29, reflecting ongoing investments[23] Operational Highlights - The company experienced a 52.90% decrease in contract liabilities, dropping from ¥66,613,643.52 to ¥31,374,796.78, attributed to a decline in revenue from in vitro diagnostic products[7] - The company reported a significant increase in other non-current assets, which rose by 109.44% to ¥33,572,204.71 due to increased prepayments for production and R&D equipment[7] - The company plans to focus on expanding its conventional product market and developing rapid testing for food safety and animal diagnostics[15][16] - Six new patents were granted during the reporting period, including one domestic invention patent and one design patent[16] - The subsidiary, Shenzhen Ai Doctor Biotechnology Co., is enhancing its product innovation and accelerating the acquisition of new veterinary drug certificates[17] - The company has successfully launched a series of bovine early pregnancy detection products and obtained production approval for several diagnostic kits[17] - The company aims to maintain its first-mover advantage in the animal diagnostics field through product innovation and regulatory compliance[17] - The company will adjust its business focus to ensure sustainable health development in response to global market changes[16] - Shenzhen Xiupu Biotechnology Co., Ltd. was recognized as a high-tech enterprise, with the certificate number GR202244205593, valid for three years from December 19, 2022[18] - The company registered 18 new Class II medical device products domestically, including IL-6, Myo, and SAA testing kits, enhancing its product portfolio in various medical fields[19] Investment and Expenses - The company incurred financial expenses of -671,493.01 CNY in Q1 2023, a decrease from 109,037.25 CNY in the same period last year, reflecting better financial management[27] - The company’s investment income showed a loss of ¥3,718,625.02, a decline of 447.26% compared to a profit of ¥1,070,843.57 in the previous year[8] - Research and development expenses increased to 18,391,842.45 CNY in Q1 2023, up from 15,605,979.98 CNY in Q1 2022, indicating a focus on innovation[27] - Total operating costs for the first quarter were CNY 94,325,423.68, compared to CNY 155,220,845.49 in the previous year[25] - The company reported a gross profit margin decline, with operating costs at CNY 45,522,665.69 against the revenue of CNY 60,707,585.25[25] - Investment activities generated a net cash flow of 23,962,684.77 CNY in Q1 2023, compared to 15,956,035.85 CNY in Q1 2022, indicating improved investment performance[31]

Financial Performance - The company reported a total revenue of RMB 400 million for the year 2022, representing a year-on-year increase of 15%[7]. - The company reported a gross margin of 60%, maintaining a stable profitability despite market fluctuations[7]. - The company reported a total revenue of 35,664.99 million CNY with a net profit of 5,818.68 million CNY for the period[139]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year, representing a growth of 25% year-over-year[179]. - The company reported a significant increase in revenue for 2022, with total revenue reaching CNY 1.5 billion, representing a year-on-year growth of 25%[193]. - The company achieved a remarkable 397.14% increase in international revenue, which reached approximately ¥303.46 million, compared to ¥61.04 million in the previous year[96]. - The company’s revenue from the food rapid testing business was ¥184,943,164.19, with a gross margin of 67.00%, showing a year-on-year increase of 1.32% in revenue but a decrease of 5.28% in gross margin[97]. - The in vitro diagnostic business generated approximately ¥499.44 million, which is 72.71% of total revenue, showing a significant year-on-year growth of 20.34%[95]. - The company’s total assets reached RMB 178,002,948.00 by the end of the reporting period[128]. - The total assets of the company reached 2 billion RMB, with a debt-to-equity ratio of 0.5, indicating a strong financial position[179]. Profitability and Earnings - The net profit attributable to shareholders decreased by 64.92% to ¥82,965,490.95 in 2022 from ¥236,507,393.22 in 2021[24]. - Basic earnings per share fell by 65.00% to ¥0.21 in 2022 from ¥0.60 in 2021[24]. - The net profit after deducting non-recurring gains and losses was ¥65,469,565.40, down 69.36% from ¥213,698,482.19 in the previous year[24]. - The company’s continuous operating capability is uncertain as indicated in the latest audit report[24]. - The company achieved a gross margin of 60%, reflecting improved operational efficiency and cost management[179]. - The company reported a gross margin improved to 60% in 2022, up from 55% in 2021, reflecting better cost management and pricing strategies[199]. Research and Development - Research and development expenses increased by 25% in 2022, reflecting the company's commitment to innovation[7]. - The company invested 111.42 million yuan in R&D, representing a 53.82% increase from the previous year[80]. - The company’s R&D investment amounted to ¥111,417,764.52 in 2022, representing 16.22% of its operating revenue[108]. - The number of R&D personnel increased by 16.28% from 172 in 2021 to 200 in 2022, with R&D personnel now accounting for 31.00% of the total workforce[108]. - The company has maintained a high level of R&D investment, resulting in a robust pipeline of innovative products and technologies, contributing to its competitive advantage[63]. - The company is focusing on developing high-throughput, automated, and information-based testing products to improve its product structure[142]. - The company is collaborating with research institutions to enhance R&D depth and breadth, focusing on protecting core technologies and retaining talent through effective incentive mechanisms[151]. Market Expansion and Strategy - The company aims to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2025[7]. - The company is actively expanding its market presence and product offerings in the animal diagnostics sector, driven by increasing demand for disease prevention in livestock and pets[60]. - The company is expanding its business into in vitro diagnostics and animal diagnostics, which requires enhanced management capabilities to mitigate risks associated with rapid growth[154]. - The company is exploring potential mergers and acquisitions to enhance its technological capabilities and market reach[7]. - The company plans to optimize its POCT business structure and expand its market presence in the US and Latin America, particularly with toxicology products[143]. - The company is actively pursuing new technologies to enhance its product portfolio and competitive edge[176]. - The company is expanding its market presence, targeting an increase in international sales by 30% in the next fiscal year[193]. Product Development and Innovation - The company plans to invest in new product development, focusing on enhancing its immunological testing capabilities and expanding its product line[7]. - The company launched several new products, including a series of bovine early pregnancy detection products and various diagnostic kits, which have received production approval[86]. - The company has developed a comprehensive in-house production capability for antigens and antibodies, with over 120 self-produced antigens and 140 self-produced antibodies now in mass production, ensuring product quality stability[64]. - The company has successfully developed rapid testing products for food safety, with a significant increase in market demand driven by national regulatory improvements[54]. - The company is focusing on the rapid testing technology for food safety, which is expected to drive product performance growth as consumer awareness increases[57]. - The company is actively seeking strategic partnerships with suppliers to ensure a stable supply of critical raw materials and maintain price stability[153]. Risk Management and Compliance - The company identified potential risks including regulatory changes and market competition, with strategies in place to mitigate these risks[7]. - The company is actively monitoring policy changes in the food safety testing industry to mitigate risks associated with regulatory adjustments[148]. - The company has established a robust governance structure to ensure compliance with regulations and protect shareholder rights, particularly for minority shareholders[159]. - The company maintains independence from its controlling shareholders, ensuring autonomous operations across business, personnel, assets, and finances[160]. Shareholder and Management Structure - The company has established clear guidelines for the general manager's responsibilities and has not identified any violations of management protocols[163]. - The company has conducted multiple shareholder meetings with participation rates ranging from 66.08% to 74.95%[172]. - The company reported a total of 102,282,778 shares, with 12,427,502 shares being reduced from restricted stock[174]. - The company experienced a change in management, with several key personnel resigning, including the former General Manager, Lu Hehua, and the former Secretary of the Board, Zhang Yukun[175]. - The company appointed new executives, including Xiao Zhaoli as General Manager and several others as Vice General Managers on May 6, 2022[175]. - The board consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[161].

证券代码：300942 证券简称：易瑞生物 编号：2022-005 投资者关系活动记录表 1 / 5 深圳市易瑞生物技术股份有限公司 | --- | --- | --- | --- | |-----------------------|-------------------------------------------|------------------------------------------------------------|---------------------------| | 投资者关系活 \n动类别 | 特定对象调研 \n 业绩说明会 \n 现场参观 | 分析师会议 \n 新闻发布会 \n 其他 | 媒体采访 \n 路演活动 | | 参与单位名称 | 国信证券股份有限公司：曾光 | | | | 及人员姓名 | 南京盛泉恒元投资有限公司：张战辉 | | | | | | 深圳市前海锐意资本管理有限公司：肖晖、刘翎 | | | 时间 | 2022 年 11 月 30 日下午 | 15:00-17:00 | | | | | | | | 地点 | 公司会议室 | | | | 上市公司接待 | ...

证券代码：300942 证券简称：易瑞生物 编号：2021-001 投资者关系活动记录表 | --- | --- | --- | --- | |--------------|------------------------------|----------------------------------------------------------|-------------------------| | | | | | | 投资者关系活 | | □特定对象调研 □分析师会议 □媒体采访 | ☑ | | 动类别 | 业绩说明会 | □新闻发布会 □路演活动□现 | | | | 场参观 | □其他（请文字说明其他活动内容） | | | | | | | | 参与单位名称 | 线上参与公司 2020 | 年度网上业绩说明会的投资者 | | | 及人员姓名 | | | | | 时间 | 2021 年 5 月 17 日 | 15:00-17:00 | | | 地点 | 全景网 " 投资者关系互动平台 | " （ http://ir.p5w.net | ） | | 上市公司接待 | | 总经理卢和华先生，独立董事何祚文 ...

投资者关系活动记录表 参与单位名称 New Silk Road Investment Pte Ltd.，冯昕先生、罗慧丽女士 及人员姓名 证券代码：300942 证券简称：易瑞生物 编号：2021-002 深圳市易瑞生物技术股份有限公司 | --- | --- | --- | --- | |--------------|--------------|------------|--------------------------------| | | | | | | 投资者关系活 | 特定对象调研 | 分析师会议 | 媒体采访 | | 动类别 | 业绩说明会 | 新闻发布会 | 路演活动 | | | 现场参观 | | 其他（请文字说明其他活动内容） | | --- | --- | |--------------|-------------------------------------------------------------------| | 时间 | 2021 年 11 月 17 日 13:30-14:40 | | 地点 | 公司会议室 | | 上市公司接待 | 董事会秘书兼副总经理：张煜堃先生 | ...